Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Zheng, Xiaohui ^a   Ding, Ning ^a   Song, Yuqin ^a   Feng, Lixia ^a   Zhu, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Apoptosis; BCR; Bruton's tyrosine kinase; Germinal center B cell like diffuse large B cell lymphoma

Indexed keywords

BRUTON TYROSINE KINASE; CASPASE 3; IBRUTINIB; LIPOCORTIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

APOPTOSIS; ARTICLE; CELL VIABILITY; CELL VIABILITY ASSAY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GERMINAL CENTRE B CELL LIKE DIFFUSE LARGE B CELL LYMPHOMA; HUMAN; HUMAN CELL; IC 50; LARGE CELL LYMPHOMA; LYMPHOMA CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84899081280     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-14-32     Document Type: Article

References (32)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511. 10.1038/35000501, 10676951.
2. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(25):1937-1947. 10.1056/NEJMoa012914, 12075054.
3. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007, 26(25):3603-3613. 10.1038/sj.onc.1210376, 17530014.
4. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23(22):5027-5033. 10.1200/JCO.2005.09.137, 15955905.
5. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002, 296(5573):1641-1642. 10.1126/science.1071546, 12040177.
6. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118(16):4313-4320. 10.1182/blood-2011-06-338855, 21816833.
7. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010, 362(15):1417-1429. 10.1056/NEJMra0807082, 20393178.
8. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005, 5(4):251-262. 10.1038/nrc1589, 15803153.
9. Hussain A, Yu L, Faryal R, Mohammad DK, Mohamed AJ, Smith CI. TEC family kinases in health and disease-loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. FEBS J 2011, 278(12):2001-2010. 10.1111/j.1742-4658.2011.08134.x, 21518255.
10. Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 2004, 22:563-598. 10.1146/annurev.immunol.22.012703.104721, 15032589.
11. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013, 6(1):88. 10.1186/1756-8722-6-88, 3843585, 24261963.
12. Afar DE, Park H, Howell BW, Rawlings DJ, Cooper J, Witte ON. Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol 1996, 16(7):3465-3471. 231341, 8668162.
13. Fluckiger AC, Li Z, Kato RM, Wahl MI, Ochs HD, Longnecker R, Kinet JP, Witte ON, Scharenberg AM, Rawlings DJ. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J 1998, 17(7):1973-1985. 10.1093/emboj/17.7.1973, 1170543, 9524120.
14. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002, 195(12):1647-1652. 10.1084/jem.20020408, 2193563, 12070292.
15. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004, 41(6-7):599-613.
16. Jiang A, Craxton A, Kurosaki T, Clark EA. Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med 1998, 188(7):1297-1306. 10.1084/jem.188.7.1297, 2212500, 9763609.
17. Tomlinson MG, Woods DB, McMahon M, Wahl MI, Witte ON, Kurosaki T, Bolen JB, Johnston JA. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. BMC Immunol 2001, 2:4. 10.1186/1471-2172-2-4, 32313, 11410123.
18. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013, 12(3):229-243. 10.1038/nrd3937, 23449308.
19. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013, 6:59. 10.1186/1756-8722-6-59, 3751776, 23958373.
20. Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014, 3(1):4. 10.1186/2162-3619-3-4, 3913970, 24472371.
21. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(1):58-61. 10.1002/cmdc.200600221, 17154430.
22. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(23):6287-6296. 10.1182/blood-2011-01-328484, 3122947, 21422473.
23. Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 2013, 37(10):1271-1277. 10.1016/j.leukres.2013.07.028, 23962569.
24. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1):88-94. 10.1200/JCO.2012.42.7906, 23045577.
25. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194(12):1861-1874. 10.1084/jem.194.12.1861, 2193582, 11748286.
26. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11(1):28-40.
27. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(7277):88-92. 10.1038/nature08638, 2845535, 20054396.
28. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113(13):3050-3058. 10.1182/blood-2008-07-170415, 19074730.
29. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114(5):1029-1037. 10.1182/blood-2009-03-212837, 19491390.
30. Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP, Ye F, Zhang D, Knowles DM, Wang YL. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008, 22(9):1755-1766. 10.1038/leu.2008.163, 18596745.
31. Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118(24):6342-6352. 10.1182/blood-2011-02-333773, 22025527.
32. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119(5):1182-1189. 10.1182/blood-2011-10-386417, 22180443.